From lab to clinic: translating stretchable bioelectronics into scalable brain interfaces

30th October 2025

Timing : 1 pm ET

Please use this zoom link for joining the webinar

For a list of all talks at the NanoBio seminar Series Fall'25, see here

The convergence of neuroscience, materials science, and microengineering is redefining how we interface with the brain. Traditional brain implants remain orders of magnitude stiffer than neural tissue, leading to poor long-term integration and limited clinical adoption. At Neurosoft Bioelectronics, we develop soft and stretchable neural interfaces that conform to the brain and can be deployed through minimally invasive procedures, enabling stable and high-fidelity access for both recording and stimulation. In this talk, I will present our initial preclinical results and describe how we have translated soft bioelectronic technologies from academic research to clinical use. I will also discuss our broader vision for applying these interfaces to neurological indications such as epilepsy and tinnitus, and for building scalable Brain–Computer Interfaces.

Dr. Nicolas Vachicouras

CEO & Co-Founder, Neurosoft Bioelectronics

Nicolas Vachicouras graduated with a BSc and MSc in Microengineering from the Swiss Federal Institute of Technology in Lausanne (EPFL) in 2014. He conducted his Master’s thesis at Harvard Medical School, contributing to the development of neural technologies for deafness. He then pursued a PhD in Microelectronics at EPFL, focusing on soft neural interfaces at the Laboratory of Prof. Stéphanie Lacour. During his PhD, Nicolas also worked as an R&D consultant for Aleva Neurotherapeutics, a neuromodulation start-up targeting Parkinson’s disease. After graduating in 2019, Nicolas co-founded Neurosoft Bioelectronics, where he serves as CEO. The company develops implantable brain interfaces using stretchable electrodes for recording and stimulation of the human brain. In addition to raising ~$13M in funding, he has been actively involved in establishing a medical-grade in-house manufacturing line for neural interfaces and initiating first-in-human studies for epilepsy monitoring in the USA and Europe.